Angeles Wealth Management LLC Grows Holdings in Boston Scientific Corporation $BSX

Angeles Wealth Management LLC grew its stake in Boston Scientific Corporation (NYSE:BSX) by 14.1% during the second quarter, Holdings Channel.com reports. The fund owned 4,983 shares of the medical equipment provider’s stock after acquiring an additional 617 shares during the period. Angeles Wealth Management LLC’s holdings in Boston Scientific were worth $535,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Sound Income Strategies LLC grew its holdings in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares in the last quarter. 1248 Management LLC acquired a new position in shares of Boston Scientific in the first quarter valued at approximately $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific in the first quarter valued at approximately $27,000. Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Boston Scientific in the second quarter valued at approximately $37,000. Finally, Activest Wealth Management grew its holdings in shares of Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 373 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares of the company’s stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 174,214 shares of company stock worth $17,972,457. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BSX. Needham & Company LLC restated a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a report on Friday. Robert W. Baird lifted their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Wells Fargo & Company boosted their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Finally, Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $120.71.

Boston Scientific Trading Up 1.5%

NYSE BSX opened at $99.20 on Friday. The firm has a 50 day moving average of $101.29 and a two-hundred day moving average of $101.74. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $146.99 billion, a PE ratio of 59.05, a price-to-earnings-growth ratio of 2.35 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the prior year, the business posted $0.62 EPS. The company’s revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.